WUHAN YZY BIOPHARMA CO., LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.45 HKD | 0.00% |
|
0.00% | -16.29% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Wuhan YZY Biopharma Co Ltd is a China-based company principally engaged in the research, development, production and sales of pharmaceuticals. The Company is mainly engaged in the research, development and industrialization of bispecific antibody drugs. The Company's main products include anti-PD1&anti-CD3, anti-CD19&anti-CD3, and anti-CDX&CD3. The Company's drug products are mainly used in major diseases such as tumor, immunity, inflammation, cardiovascular and infection.
| 1st Jan change | Capi. | |
|---|---|---|
| -16.29% | 185M | |
| +12.30% | 118B | |
| +12.15% | 106B | |
| -8.14% | 23.4B | |
| -0.29% | 22.1B | |
| -9.28% | 18.34B | |
| -41.70% | 16.59B | |
| -15.33% | 15.97B | |
| +5.80% | 14.03B | |
| +28.03% | 11.67B |
- Stock Market
- Equities
- 2496 Stock
- News Wuhan YZY Biopharma Co., Ltd.
- Wuhan YZY Biopharma Raises HK$121 Million in Hong Kong IPO, Prices at Bottom of Range
